Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 1112, pseudogene (RNU6-1112P) is a processed pseudogene related to the highly conserved U6 small nuclear RNA (snRNA) family[2][4]. The functional U6 snRNA is a core component of the spliceosome, the complex responsible for catalyzing pre-mRNA splicing in the nuclei of eukaryotic cells, but RNU6-1112P itself does not encode a functional product or participate in splicing[1][3][4]. Pseudogenes like RNU6-1112P are typically produced through retrotransposition (L1-mediated reverse transcription) and can be detected as truncated, non-functional copies dispersed throughout the genome[4]. There is no evidence that RNU6-1112P acts as a therapeutic target, biomarker, or has any known pathology or pharmacology associated. Its presence mainly reflects genome architecture and retrotransposition activity[4][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1112, pseudogene (RNU6-1112P).